Abstract: The cytokine ML-1 is a target for treating airway inflammation. Candidate therapeutic agents for treating airway inflammation can be screened for the ability to bind to an ML-1 protein or polynucleotide, from the ability to decrease functional properties of ML-1, or for the ability to decrease ML-1 gene expression. Pharmaceutical compositions comprising such reagents can be used to treat airway inflammation associated with a variety of lung disorders, such as asthma, chronic obstructive pulmonary disease, emphysema, allergic inflammatory responses, and cystic fibrosis.